tirzepatide surmount after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial The SURMOUNT-MAINTAIN trial will help

Patients with IBS-C (constipation-dominant) may experience worsening symptoms within weeks of starting therapy, while those with IBS-D (diarrhea-dominant) sometimes report improvement in urgency and stool frequency

Here we break down some of the key findings: Improved Insulin Sensitivity and Metabolic Health One of the first major MOTS-c studies showed a dramatic impact on metabolism

Within this context, the gut microbiota can be considered a potential component of this integrated system, given its involvement in enteroendocrine and incretin signaling

and infections associated with injection in a peripheral joint space such as the knee, shoulder or ankle